A webinar discussing the ongoing Shaping the Health of Adolescents in Zimbabwe (SHAZ!) study. 2014 AVAC Fellow Definate Nhamo reviewed key findings from SHAZ! and previewed how she will use them to shape some of her advocacy in her 2014 Fellowship year.
Avac Event
Shaping the Health of Adolescents in Zimbabwe (SHAZ!): Key findings and recommendations
Avac Event
What are the HIV prevention needs of people who use drugs in Eastern Europe?
Hosted jointly by NAM and AVAC, the second webinar in the 2014 series covered harm reduction, pre-exposure prophylaxis (PrEP) and Hepatitis C prevention in people who use drugs, with news from relevant studies and new initiatives in Europe.
Avac Event
The Latest on Lab Tests, Lubed Monkeys, and Lube-Using Humans
Why should you care if sexual lubricants are safe or not? What do we know, and what do we need to know? What’s happening to move the issue of lube safety forward? What’s not happening? Join IRMA and AVAC and our expert guests who will provide an exciting update on the latest in lubricant safety and help us answer these important questions.
Dr. Ellen Kersh of the CDC will begin the webinar with a discussion of a rectal challenge study done in monkeys using a hyperosmolar lube as a model for HIV risk and rectal lubricant use. Following, Dr. Kevin Rebe of Anova Health Institute will share findings from lube safety experiments he led using common lubes in South Africa, and Dr. Pamina Gorbach of UCLA will present brand new behavioral data a multi-site study at US STD clinics. IRMA’s own Marc-Andre LeBlanc, our resident lube expert, will then provide a current snapshot of lubricant advocacy activities, including ways you can get involved to make progress on the lube safety agenda.
View the full flash webinar here.
Avac Event
PrEP @ 2 years—and still counting women in…
The US Women & PrEP Working Group, SisterLove and AVAC hosted a webinar marking the two-year anniversary of the FDA licensing of Truvada as PrEP in the US.
This webinar provided an opportunity to share updates and resources in the field and discussed how far we’ve moved in getting women involved in the rollout of PrEP. The webinar reviewed what we know and don’t know about women’s motivations and barriers to consider daily oral PrEP as an intervention. Speakers included Karen Hoover from the US CDC, Judy Auerbach from the University of California at San Francisco, Alan McCord from Project Inform, and moderator, Dazon Dixon Diallo of SisterLove and the US Women & PrEP Working Group.
Avac Event
From the Booty’s Point of View: Using perceptibility data to inform rectal microbicide development
Rectal microbicide development has made strides in recent years, but, as with vaginal microbicides, adherence remains a concern for product developers.
There are two “P” words we have always loved – pleasure and prevention.
Perceptibility is a new strategy for evaluating what products feel like and how they “behave” in the body (in the booty as well!), during insertion, everyday activities, and, of course, during sex. The hope is that, by understanding how product characteristics impact how they are felt and understood by potential users, we can better design products for pleasure and prevention.
In this presention, Kate Morrow explained the third “P” word, perceptibility. She told us why it is so crucial to both pleasure and HIV prevention, how the perceptibility process works, and how it helps create rectal microbicide products that people actually want to use.
Avac Event
2015 AVAC Advocacy Fellowship Informational Call
This webinar provided an overview of the AVAC Advocacy Fellowship and the 2015 application process for aspiring candidates. The Fellowship team at AVAC was joined by current and alumni Fellows to answer questions and discuss their experiences. For more information, visit the Fellowship application page.
Avac Event
Do we need a new paradigm for HIV vaccine development?
The Canadian HIV Vaccine Initiative (CHVI) Research and Development Alliance Coordinating Office (ACO) invites you to join us for a webinar entitled “Do we need a new paradigm for HIV vaccine development?” with Dr. José Esparza who will give participants a greater understanding of some of the lessons learned after 30 years of HIV vaccine development.
This webinar will include a brief history of HIV vaccine development, some reflections about why it has been so difficult, and personal recommendations to accelerate the development of an HIV vaccine.
With José Esparza MD, PhD, formerly of the Bill & Melinda Gates Foundation; and Adjunct Professor, Institute of Human Virology, University of Maryland School of Medicine
To register contact [email protected]
Avac Event
State of the Art HIV Cure: Where are we now and where are we going?
The field of cure research is evolving and expanding, with various proposed trials that require informed engagement from many stakeholders. Plenary speaker, Jintanat Ananworanich, provides an update, discusses research, and answers questions.
Avac Event
UNAIDS, Targets and Civil Society
In Melbourne, UNAIDS launched a new initiative known as “90-90-90”, which lays out new targets for testing, treatment and virologic suppression. Where did these targets come from, what do they mean—and where does prevention fit in? Chris Collins, Chief of the Community Mobilization Division at UNAIDS addressed these questions and more.
Avac Event
Latest developments in VMMC research and implementation
AIDS 2014 brought more updates on voluntary medical male circumcision (VMMC) including new data on risk behaviors in circumcised men, the impact of cash transfers as part of VMMC programming and more. Kenyan researcher and implementer Kawango Agot reviewed the latest findings.